Analysis of Natco Pharma - Favourable High Court Ruling on Risdiplam Generic

Natco Pharma Ltd. has received a significant positive legal outcome from the Delhi High Court on October 10, 2025. The court upheld a previous ruling, dismissing an appeal from Roche, and has definitively cleared the path for Natco to launch its generic version of Risdiplam in the Indian market. Risdiplam is a critical drug for the treatment of Spinal Muscular Atrophy (SMA), a rare genetic disorder. Market & Financial Implications: This verdict is a major catalyst for the company, unlocking a substantial market opportunity. Immediate Commercialization: Natco can now proceed with the immediate launch and commercialization of its generic Risdiplam. Disruptive Pricing Strategy: The company has announced a Maximum Retail Price (MRP) of ₹15,900 per bottle. This represents a drastic price reduction compared to Roche's imported brand, Evrysdi, which is priced at approximately ₹6 lakh per bottle. This competitive pricing strategy is poised to capture significant market share by making this life-saving therapy accessible to a much broader patient base in India. Revenue Potential: The successful launch is expected to open a new and meaningful revenue stream for Natco Pharma, addressing a high-value, unmet medical need. Stock Performance: The market has reacted favourably to this news, with the company's shares surging up to 5% during the trading session. The stock is currently trading 4% higher at ₹845.3. While this provides a positive near-term boost, it is noted that the stock is trading at a significant discount (over 45%) from its 52-week high of over ₹1,500, indicating potential for re-rating based on successful execution. Conclusion: This legal victory is a pivotal development for Natco Pharma, enabling it to enter a niche therapeutic area with a competitively priced product. The focus will now shift to the company's execution of its launch and market penetration strategy. Sources